Marshall Wace Portfolio holdings
Marshall Wace is a British firm that runs long/short hedge funds. Its strategies combine computer-driven and traditional company analysis, applied worldwide and mostly to long/short equity. Paul Marshall, formerly head of European equities at Mercury Asset Management, and Ian Wace, formerly head of equities trading at Deutsche Bank, founded it in 1997. In 2002 it launched TOPS, a system that gathers investment ideas from equity professionals and uses algorithms to turn them into stock portfolios. In 2015 Marshall Wace formed a long-term partnership with KKR, a private equity and credit investor that took an ownership interest in the firm.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$9.9B |
| 2 |
Costco
COST
|
+$907M |
| 3 |
AbbVie
ABBV
|
+$643M |
| 4 |
JPMorgan Chase
JPM
|
+$609M |
| 5 |
Bank of America
BAC
|
+$567M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.03B |
| 2 |
Mercado Libre
MELI
|
+$528M |
| 3 |
Broadcom
AVGO
|
+$514M |
| 4 |
Sandisk
SNDK
|
+$507M |
| 5 |
Marvell Technology
MRVL
|
+$499M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 34.91% |
| 2 | Technology | 20.64% |
| 3 | Consumer Discretionary | 9.1% |
| 4 | Healthcare | 8.21% |
| 5 | Financials | 7.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2651
PRA Group
PRAA
$754M
| $338K | ﹤0.01% |
+17,799
| New | +$316K |
2026 Q2
0 quarters
|
|
2652
Energys Group
ENGS
$199M
| $336K | ﹤0.01% |
+138,207
| New | +$211K |
2026 Q2
0 quarters
|
|
2653
CALL
Merck
MRK
$361B
| $334K | ﹤0.01% |
+2,600
| New | +$304K |
2026 Q2
0 quarters
|
|
2654
Relay Therapeutics
RLAY
$4.26B
| $334K | ﹤0.01% |
17,843
-923,982
| -98% | -$13.4M |
2026 Q1
1 quarter
|
|
2655
Willdan Group
WLDN
$1.18B
| $333K | ﹤0.01% |
4,215
-22,734
| -84% | -$1.94M |
2023 Q1
13 quarters
|
|
2656
iShares Select U.S. REIT ETF
ICF
$1.97B
| $333K | ﹤0.01% |
+4,920
| New | +$331K |
2026 Q2
0 quarters
|
|
2657
Zillow
ZG
$7.21B
| $333K | ﹤0.01% |
10,600
+1,500
| +16% | +$57.9K |
2026 Q1
1 quarter
|
|
2658
Lakeland Financial Corp
LKFN
$1.51B
| $332K | ﹤0.01% |
5,382
-12,291
| -70% | -$741K |
2025 Q4
2 quarters
|
|
2659
Centerspace
CSR
$989M
| $332K | ﹤0.01% |
+5,907
| New | +$372K |
2026 Q2
0 quarters
|
|
2660
CALL
BlackBerry
BB
$5.4B
| $331K | ﹤0.01% |
+26,200
| New | +$183K |
2026 Q2
0 quarters
|
|
2661
PUT
Wingstop
WING
$3.93B
| $329K | ﹤0.01% |
1,900
-1,900
| -50% | -$299K |
2026 Q1
1 quarter
|
|
2662
GCM Grosvenor
GCMG
$770M
| $329K | ﹤0.01% |
26,752
-379,752
| -93% | -$4.15M |
2025 Q1
5 quarters
|
|
2663
Allied Gold Corp
AAUC
$2.74B
| $328K | ﹤0.01% |
+13,810
| New | +$390K |
2026 Q2
0 quarters
|
|
2664
iShares MSCI Japan Small-Cap ETF
SCJ
$235M
| $328K | ﹤0.01% |
+3,118
| New | +$322K |
2026 Q2
0 quarters
|
|
2665
Portfolio Building Block World Pharma and Biotech Index ETF
PBPH
$1.08B
| $326K | ﹤0.01% |
+12,012
| New | +$306K |
2026 Q2
0 quarters
|
|
2666
Sabre
SABR
$670M
| $324K | ﹤0.01% |
154,907
+5,107
| +3% | +$8.95K |
2026 Q1
1 quarter
|
|
2667
Vera Therapeutics
VERA
$2.2B
| $323K | ﹤0.01% |
+7,531
| New | +$281K |
2026 Q2
0 quarters
|
|
2668
Skillsoft
SKIL
$48M
| $322K | ﹤0.01% |
+62,256
| New | +$414K |
2026 Q2
0 quarters
|
|
2669
Companhia Siderúrgica Nacional
SID
$1.03B
| $322K | ﹤0.01% |
350,283
-637,833
| -65% | -$798K |
2025 Q4
2 quarters
|
|
2670
Pure Cycle
PCYO
$255M
| $322K | ﹤0.01% |
30,060
-45,458
| -60% | -$497K |
2025 Q4
2 quarters
|
|
2671
Denison Mines
DNN
$2.15B
| $321K | ﹤0.01% |
104,965
-361,145
| -77% | -$1.26M |
2025 Q3
3 quarters
|
|
2672
iShares MSCI Netherlands ETF
EWN
$634M
| $321K | ﹤0.01% |
+4,565
| New | +$298K |
2026 Q2
0 quarters
|
|
2673
Anika Therapeutics
ANIK
$290M
| $321K | ﹤0.01% |
21,918
-2,013
| -8% | -$29.8K |
2025 Q2
4 quarters
|
|
2674
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.7B
| $320K | ﹤0.01% |
+4,000
| New | +$320K |
2026 Q2
0 quarters
|
|
2675
Grupo Aeromexico SAB de CV
AERO
$2.37B
| $319K | ﹤0.01% |
17,746
-4,347
| -20% | -$69.8K |
2025 Q4
2 quarters
|
|
Similar funds
Marshall Wace's Q2 2026 Portfolio in Review
As of Q2 2026, Marshall Wace held 3,898 positions worth $127B, up 26% from $100B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Marshall Wace deployed $9.28B of net new capital in Q2 2026, opening 771 new positions and adding to 1,083 existing holdings. Its largest new stake was LPL Financial: 975,627 shares worth $275M.
By sector, the portfolio is most concentrated in Miscellaneous at 35% of assets, up from 30% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was NVIDIA, an estimated $1.03B trimmed.
- Marshall Wace's largest Q2 2026 buy was LPL Financial: 975,627 shares worth $275M.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $9.9B increase.
- Marshall Wace's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $1.03B.
- Marshall Wace fully exited Merck in Q2 2026, selling an estimated $325M.
- Marshall Wace's ten largest holdings make up 38% of its $127B portfolio in Q2 2026.
- Marshall Wace opened 771 new positions and closed 795 in Q2 2026.
- Marshall Wace's portfolio value rose 26% quarter-over-quarter to $127B.
Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.